Cayman Ganglioside Gm1 Asialo Polyclonal Antibody; Size- 100 Micr

The binding of insulin-like growth factor 1 (IGF-1) to the IGF-1 receptor (IGF-1R) promotes cell growth while inhibiting apoptotic pathways. Overexpression of IGF-1R is found in certain solid tumors and hematologic neoplasias.^, However, insulin receptor (InsR) signaling can compensate for IGF-1R inhibition. Linsitinib is a dual inhibitor of IGF-1R and InsR kinases (IC₅₀s = 35 and 75 nM, respectively). It also inhibits InsR-related receptor (IC₅₀ = 75 nM) but is without effect (IC₅₀ > 10 µM) against a large panel of other kinases. Linsitinib inhibits proliferation of a variety of tumor cell lines in vitro and has antitumor efficacy in an IGF-1R-driven xenograft mouse model when administered orally. A rapid, non-invasive method to predict the pharmacodynamic response to linsitinib has been reported.

WARNING This product is not for human or veterinary use.